# Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases

> **NCT06848842** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 40 (estimated)

## Conditions studied

- Colorectal Liver Metastases

## Interventions

- **DRUG:** Ivonescimab plus chemotherapy

## Key facts

- **NCT ID:** NCT06848842
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-18
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06848842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06848842, "Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06848842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*